SGCB and chronic kidney disease: In addition to these beneficial findings with sGC activators and sGC stimulators in obese ZSF1 rats, e.g., inhibition of kidney function decline indicated by significant reduction in proteinuria and decrease in kidney damage biomarkers, it is difficult to predict the molecular mechanism of action of runcaciguat in CKD.